Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Ultragenyx Germany GmbH, Friedrichstr. 191, 10117, Berlin, Germany
Mepsevii 2 mg/mL concentrate for solution for infusion.
Pharmaceutical Form |
---|
Concentrate for solution for infusion (sterile concentrate). Colourless to slightly yellow solution. |
Each mL of concentrate contains 2 mg vestronidase alfa*. Each vial of 5 mL concentrate contains 10 mg vestronidase alfa.
* Vestronidase alfa is a recombinant form of human beta-glucuronidase (rhGUS) and is produced in Chinese Hamster Ovary cell culture by recombinant DNA technology.
Excipient(s) with known effect: Each vial contains 17.8 mg sodium.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Vestronidase alfa |
Vestronidase alfa is a recombinant form of human betaglucuronidase (GUS) and is intended to provide exogenous GUS enzyme for uptake into cellular lysosomes and subsequent catabolism of accumulated glycosaminoglycans (GAGs) in affected tissues. |
List of Excipients |
---|
Sodium dihydrogen phosphate dihydrate |
Colourless glass vial (Ph. Eur. Type I) with a rubber stopper with fluoro-resin coating, and an aluminium over seal with a plastic flip-off cap.
Pack size: 1 vial containing 5 mL of concentrate for solution for infusion.
Ultragenyx Germany GmbH, Friedrichstr. 191, 10117, Berlin, Germany
EU/1/18/1301/001
Date of first authorisation: 23 August 2018
Drug | Countries | |
---|---|---|
MEPSEVII | Austria, Brazil, Estonia, Spain, France, Croatia, Ireland, Italy, Japan, Lithuania, Poland, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.